Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases
MARLBOROUGH, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc., (NASDAQ:AKYA), The Spatial Biology Company®, today announced that the newly established Queensland Spatial Biology Centre (QSBC), located in Brisbane, Australia, is using the PhenoCycler-Fusion spatial biology platform as the core technology to revolutionize the way cancer and other debilitating diseases are diagnosed and treated.
Related news for (AKYA)
- Today’s Top Performers: MoBot’s Market Review 05/21/25 08:00 AM
- Don’t Miss Out: MoBot’s Latest Stock Updates 05/21/25 07:00 AM
- Akoya Biosciences Reports First Quarter 2025 Financial Results
- Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas
- Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025